Vital Signs - Managing Type 2 Diabetes: Risk vs. Reward

 

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on August 13, 2007, provides a strategic overview of recent adverse risk issues impacting Avandia. Additionally, a company spotlight is provided for DiaKine Therapeutics, a developer of innovative therapies for diabetes and related complications. Reimbursement and regulatory news from the FDA is also provided for the week of July 30 - August 3, 2007.

Table of Contents

Vital Signs - Managing Type 2 Diabetes: Risk vs. RewardVital Signs: 13 August 2007This week's issue:




Related Research

Release Date : 19-Sep-17

Region : North America

Release Date : 08-Sep-17

Region : North America

Release Date : 22-Aug-17

Region : North America

Release Date : 08-Aug-17

Region : North America

Release Date : 31-Jul-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.